What is Antengene?
Antengene Corporation Limited is a commercial-stage, R&D-driven biopharmaceutical entity dedicated to developing first-in-class and best-in-class therapeutic medicines. Since its inception in 2017, the company has established a robust pipeline of 15 clinical and pre-clinical assets, obtaining numerous investigational new drug (IND) approvals and submitting new drug applications (NDAs) in key Asia Pacific markets. Its strategic focus on treating patients beyond borders, coupled with its success in securing significant investment, positions it as a key player in the global oncology landscape.
How much funding has Antengene raised?
Antengene has raised a total of $238M across 3 funding rounds:
Series A
$21M
Series B
$120M
Series C
$97M
Series A (2017): $21M with participation from Huagai Capital, Tigermed, TF Capital, and Qiming Venture Partners
Series B (2019): $120M led by Boyu Capital
Series C (2020): $97M supported by GIC, Qiming Venture Partners, Fidelity Management & Research Company, GL Ventures, and Boyu Capital
Key Investors in Antengene
GIC
GIC is a Singaporean sovereign wealth fund established in 1981, managing the nation's foreign reserves through diverse investments in public and private markets to ensure long-term financial security.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that invests in the healthcare and technology sectors, supporting innovative companies from early-stage to growth.
Fidelity Management & Research Company
Fidelity Investments is a global financial services firm offering a comprehensive suite of investment, wealth management, and retirement solutions for individuals and institutions.
What's next for Antengene?
With the recent major strategic investment and a history of substantial capital raises, Antengene is poised for accelerated growth and expansion. The company's enterprise-level funding suggests a transition into a scaling phase, likely focusing on advancing its late-stage clinical assets, expanding its commercial reach in the Asia Pacific, and potentially pursuing further strategic partnerships or acquisitions. This financial backing will be critical in navigating the complex regulatory pathways and market entry strategies required to bring its innovative therapies to patients worldwide.
See full Antengene company page
